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ABSTRACT  
Magnetic nanoparticles (MNPs) composed of magnetite coated with oleic acid and functionalized with chitosan have been prepared to the 
targeted release of the non steroidal anti-inflammatory drug (NSAID) Diclofenac. Two procedures to incorporate the drug were explored: 
simple adsorption and covalent linkage. The impact of experimental variables such as the nature of the NSAID (commercial versus 
analytical sodium Diclofenac), its concentration and amount of coupling agent were evaluated in terms of the loading efficiency and the 
properties of interest of MNPs (size, surface functionality, stability). Loaded and unloaded MNPs were characterized by FTIR-DRIFTS 
spectroscopy, dynamic light scattering, zeta potential and transmission electron microscopy. UV-visible quantification of Diclofenac was 
achieved reaching values of loading efficiency between 11 and 27% depending on the experimental conditions. Probable mechanisms for 
drug-MNPs interactions have been proposed on the base of characterization data.                         
A nanocarrier of size lower than 150 nm, with satisfactory loading skill and high dispersion capability on water was obtained. The release 
behavior demonstrated to be independent on the presence of an external magnetic field. The properties found in these nanosystems 
result relevant in view of their effective in vivo implementation. 
Keywords: Magnetic nanoparticles; Chitosan; Diclofenac; Drug target; In vitro release. 
 
1. INTRODUCTION  
Diclofenac is one of the non steroidal anti-inflammatory drug 
(NSAID) commonly chosen for the treatment of chronic 
inflammatory diseases because of its favorable 
pharmacodynamic characteristics
1,2
. Anyway, the chronic 
treatment with this NSAID leads to some side effects, being 
gastrointestinal and kidney damage the most frequent ones. In 
the last years several drug delivery systems have been 
developed aiming to diminishing these drawbacks, being most 
of them intended for oral intake or transdermal delivery
3,4
. Even 
the development of these systems has contributed to diminish 
the side effects of this NSAID, neither of them was designed as 
intended for the targeted delivery of this therapeutic agent to 
the specific injured tissue. 
Magnetic systems of varied composition appear as an attractive 
strategy in order to target delivery of therapeutic agents to a 
specific site of the body by the aid of a magnetic field, avoiding 
or at least minimizing collateral effects associated to most 
drugs
8, 9, 10
. 
The implementation of magnetic nanocarreirs to target and 
release Diclofenac has not been explored enough according to 
the available literature
11. 
For instance, Saravanan et al. obtained 
magnetic microspheres composed by gelatin to in vivo targeted 
Diclofenac delivery under the influence of a magnet. These 
authors found that only a 5% of the drug was concentrated in 
the target site. They concluded that further studies regarding to 
the carriers formulations are necessary to achieve higher drug 
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amounts in the blank organ
8
.
 
Arias et al. have prepared 
iron/ethylcellulose (core/shell) nanoparticles loaded with 
Diclofenac sodium for arthritis treatment. In their research they 
obtained drug loading levels of about 11% by surface adsorption 
and a prolonged drug release profile
12
.  
The design of a nanocarrier composed by a magnetic core and 
functionalized with chitosan appears as an interesting 
combination for drug delivery taking into account the 
compatible biological and chemical properties of the polymer 
with the magnetic capability of the iron oxide.  
The aim of this manuscript lies in obtaining a suitable magnetic 
nanoplatform composed of magnetite coated with chitosan to 
the target of Diclofenac. The presence of the polymer is 
required, firstly to stabilize the magnetite NPs that have a 
strong tend to the aggregation after formed, and secondly to 
provide biocompatibility and reactive functional groups to the 
nanocarriers. Articles in open literature devoted to the 
preparation of magnetic systems containing chitosan are 
numerous
13, 14
 and many of them are employed to the delivery 
of varied therapeutic agents
15, 16, 17
. However the design and 
evaluation of a nanocarrier based on a combination of 
magnetite/oleic acid/chitosan and Diclofenac have not been 
earlier reported as the best of these author´s knowledge. 
In a previous work the simple adsorption of the drug was 
achieved in this kind of carrier
15
. The present contribution deals 
with the optimization of the mentioned preliminary formulation 
exploring new insights related to: i- the stability and sizes of the 
MNPs; ii- the covalent Diclofenac linkage and, iii- the release 
behavior and mechanisms for the drug-carriers interactions. 
This last aspect is missing in the actual literature regarding to 
the topic. All these issues are of relevant importance as the 
initial stage to obtain efficient nanodevices for in vivo studies.
 
 
2. MATERIALS AND METHODS 
2.1 Synthesis of magnetic nanocarriers using different 
glutaraldehyde concentrations. 
MNPs from magnetite and oleic acid (MAG/OA) were prepared 
by co-precipitation under previously studied conditions
15
.
 
Briefly, 20 mL of solutions of FeSO4·7H2O and FeCl3· 6H2O 
(Fe
2+
/Fe
3+
 molar ratio equal to 0.5) were mixed. Then 0.3 g of 
oleic acid were added in the reactor under nitrogen atmosphere 
at 70°C; and 5 mL of NaOH 5M were added drop wise. The 
incorporation of the polymer was achieved by 
nanoprecipitation: 0.3 g of MAG/OA MNPs were dispersed in 75 
mL acetone. After 15 minutes of sonication, 15 mL of a solution 
of chitosan (CS) (10.0 mg / ml) in acetic acid (50% v/v) were 
added. The resulting solid was magnetically separated with a 
high-power Nd magnet, washed with water three times and 
dried at 45°C for 24 hours. Crosslinking with glutaraldehyde 
(GA) was developed to fix CS to the magnetic core. To do this, 
50 mg MAG/OA/CS were dispersed in water and then added 
with variable concentrations of the crosslinker (i.e: 1.5, 3 and 5 
mL of an aqueous solution of glutaraldehyde (25% m/v) to 
obtain final GA concentrations of about 7.5 (1); 15 (3) and 25% 
(4) respectively. After 2 hours of reaction at 45°C under 
magnetic stirring, samples were washed with water for three 
times and dried at 45°C in an oven. In order to evaluate the 
effect of ultrasound treatment in the efficiency of crosslinking 
procedure, the formulation containing 1.5% of GA was 
sonicated for 2 hours instead of magnetic stirring (2). 
 
2.2 Incorporation of Diclofenac  
2.2.1 Simple adsorption method: aqueous dispersions 
containing 50 mg of nanocarriers and the corresponding 
amount of NSAID (25 or 50 mg) were magnetically stirred for 24 
hours at room temperature. Samples were withdrawn at 
different intervals of time to determine drug incorporation. 
2.2.2 Covalent linkage: Diclofenac was practiced by adding 
different quantities (50 or 100 µL) of GA to an aqueous 
dispersion containing 50 mg of the MNPs and the proper 
amount of the drug. Dispersions were magnetically stirred for 
24 hours at room temperature. In order to determine drug 
incorporation, samples were withdrawn at different intervals of 
time.  
In both methodologies, the influence of the nature of the drug 
was analyzed by using both a commercial available Diclofenac 
formulation and pure Diclofenac sodium.  
After the loading of the drug, the purification of MNPs was 
performed by washing with distilled water to remove non 
interacting NSAID and dried at 45°C. The resulting powder as it 
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or redispersed in water was employed for whole physico-
chemical characterization. 
 
2.3 Diclofenac quantification  
UV spectroscopic measurements were carried out to determine 
drug incorporation into the MNPs at 276 nm using a 
spectrophotometer Shimadzu 160 Japan. A calibrating curve 
relating absorbance (A) and Diclofenac concentration was 
constructed. The contribution to the absorbance of sources 
other than variations in drug concentration (mainly free 
stabilizers and electrolytes) was considered by incubating MNPs 
under the same conditions but without the drug. Drug 
incorporation was expressed as Diclofenac Loading Efficiency 
(DLE %): [loaded drug (mg)/total drug in the suspension (mg) 
×100].  
 
2.4 Characterization  
Particle hydrodynamic diameters (Dh) were determined by 
Dynamic Light Scattering (DLS) at 25°C. Dispersions were 
prepared using concentrations of about 0.1 mg/mL in both 
distilled ǁater aŶd aĐetoŶe. )eta poteŶtial ;ζͿ ŵeasureŵeŶts 
were carried out in aqueous dispersions of concentration 0.1 
mg/mL. Both determinations were performed in a Malvern 
Zetasizer for three independent measurements. Errors between 
samples were statistically analyzed and considered not 
significant. 
The presence of different components of the nanoparticles as 
well as drug incorporation was verified by Diffuse reflectance 
infrared Fourier transform spectroscopy (DRIFTS-FTIR) using a 
Thermo Scientific Nicolet 6700 spectrometer, recording spectra 
in the range 4000–400 cm-1.  A few milligrams of the samples 
were mixed manually in a mortar with KBr powder to be placed 
in the sample unit of spectrometer. 
Transmission electron microscopy (TEM, JEOL100 CXII, JEOL, 
TOKIO, Japan, 1983 from CCT, Bahía Blanca, Argentina) was 
employed to analyze particle morphology.  
Stability studies were assayed by determination of Dh after two 
months of storage of MNPs samples in the different solvent 
dispersions and at room temperature. 
High-resolution inductively coupled plasma atomic emission 
spectroscopy (ICP-AES, Shimadzu 9000) was used to evaluate 
the composition of the nanoparticles in terms of total iron 
content. For these measurements, 10 mg of MNPs were 
dissolved in 10 mL HCl 36% w/v.  
The magnetic measurements were carried out in a vibrating 
sample magnetometer (VSM), and were reported in previous 
work
17
.
 
 
2.5 In vitro release assays. 
Diclofenac release has been studied in vitro using the best 
formulation in terms of the DLE and physicochemical properties. 
The influence of an external magnetic field during the assay was 
explored. By this way, 50 mg of the drug loaded nanocarrier 
were dispersed in 5 mL PBS (pH = 7.4) and incubated at 37°C 
under magnetic stirring for 24 hours. Samples of the 
supernatants were withdrawn at prefixed times (1, 2, 3, 5, 12 
and 24 hours) and analyzed for the drug content by UV/visible 
spectroscopy. The same treatment was applied to the 
corresponding unloaded nanoparticles under both experimental 
conditions (presence and absence of the magnetic field) in 
order to be employed as blank of reaction to discard the 
contribution to the absorbance of other sources.  
 
2.6 Release data modeling 
Data obtained from in vitro release assays were fitted to the 
following mathematical models to predict the in vitro release 
kinetic: 
(a) The zero-order rate describes those systems in which drug 
release does not depend on its concentration
18
: 
C = K0 t........ (1) 
K0 is the zero-order rate constant expressed in units of 
concentration/time and t is the time. 
(b) The first-order kinetic model, where the drug release rate 
depends on its concentration [19]: 
log c = log c0 − kt / 2.303........... (2) 
being C0, the initial concentration of drug and k, the first-order 
constant. 
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(c) The Higuchi model, in which the release of drugs from an 
insoluble matrix, is described as the square root of time 
dependent process
20
:  
Q = Kt
1/2
.........
 
(3) 
K is a constant reflecting the design variables of the system. 
(d) The Hixson–Crowell model describes the release from 
systems in which there is a change in the surface area and in the 
diameter of particles or carrier
18
:  
Q0
1/3 − Qt1/3 = KHCt......... (4) 
Here, Qt is the amount of drug released in time t, Q0 is the initial 
amount of the drug and KHC is the rate constant of the Hixson–
Crowell rate equation. 
(d) Finally, the Korsmeyer model employs a semi-empirical 
equation to describe the drug release from swelling controlled 
systems
21, 22
:
 
 
Mt / M∞ = Kt
n
 .........(5) 
Mt/M∞ is the fraction of drug released at time t, K is the rate 
constant and n is the release exponent. The n value is used to 
characterize different release mechanisms. 
The goodness of fit was established by determining r
2
 
coefficients to each model. Highest (closer to 1) correlation 
coefficients are the models with best fit.  
 
3. RESULTS AND DISCUSSION   
3.1 Characterization of unloaded nanocarriers 
GA was incorporated to MNPs formulation to crosslink the CS 
moieties, avoiding its disgregation and ensuring the stability of 
the nanosystems during application.  
The influence of the GA was evaluated in terms of the evolution 
of the nanocarriers sizes. Figure 1 shows the tendency in Dh as a 
function of the GA nominal concentration using different 
solvents as dispersant media. It is not observable a straight 
trend between size and the solvent employed for the 
dispersion. It is worth noting that using the lowest 
concentration of GA (7.50 % m/v), the Dh diminishes with 
respect to the non-crosslinked nanocarrier. When ultrasonic 
treatment was implemented -at this GA concentration- a 
noticeable reduction in Dh was reached in the aqueous 
dispersion (see formulation 2 in Figure 1). Increasing  GA 
concentration, higher Dh values are recorded, which is 
reasonable knowing the GA trend to form oligomers or even 
low molecular weigth polymers by interpenetration of its 
chains
23
. The obtained PDIs values resulted lower than 0.5 using 
all the tested solvents with all samples. This fact assures an 
almost monodispersed system.   
 
Figure 1:  Dh of unloaded magnetic carriers in different 
dispersion media as a function of glutaraldehyde concentration. 
 
 
Composition of all nanocarriers was analyzed by FTIR DRIFTS 
(Figure 2). MAG spectrum shows a strong band at 588 cm
-1
, 
assignable to Fe-O stretching vibration. On the other hand, CS 
spectrum reveals the presence of bands at 3345 cm
-1
 (v O-H), 
2920 and 2854 cm
-1
 (v C-H); 1560 cm
-1
 (N-H bending vibrations) 
and 1023 cm
-1
 (v CO). Spectra corresponding to MNPs 
composed by magnetite recovered with OA and functionalized 
with CS, reveals a band around 1646 cm
-1
 assignable to 
asymmetric stretching of COO group of the OA; bands present 
near 1510 and 1428 cm
-1
 could be attributable to COO
-
 
coordinated to Fe. 
 When analyzing spectra corresponding to MNPs crosslinked 
with GA, the band associated to Fe-O stretching vibration as 
well as the bands assignable to CS above described, are 
detected. Signals corresponding to OA are masked by new 
bands from GA.  
The crosslinking reaction with GA can be evidenced by the 
appearance of a band near 1650 cm
-1
. This band is characteristic 
and indicative of the interaction between free amine groups 
from CS with aldehydic groups from GA to form stable imine 
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bonds leading to the formation of a Schiff ďase ;ʆ N=CͿ. As 
described in literature, crosslinking reaction can involve two CS 
units belonging or not to the same polymeric chain
24
. 
 
Figure 2: FTIR-DRIFTS spectra corresponding to:  magnetite, 
chitosan, MNPs and MNPs crosslinked with different 
glutaraldehyde concentrations (% m/v). 
 
Comparing FTIR spectra of formulations containing GA to the 
corresponding to raw MNPs, it is notable an increasing in the 
intensity of the band located near 2924 cm
-1
, attributed to C-H 
and CH2 stretching vibration of CS (See arrow in Figure 2). This 
fact is associated to the contribution of GA during crosslinking 
process of polymeric chains. It is worth noting that such band is 
clearly more intense in formulation 2 (See circled signals in 
Figure 2) comparing with the rest of nanocarriers and, especially 
to nanocarrier 1, where the same concentration of crosslinking 
agent was used (7.50%).  
FTIR DRIFTS analyses assure that prepared nanocarriers present 
all the components - i.e. CS, MAG/OA as well as GA. The 
application of ultrasound treatment favored the interactions 
GA-CS, providing extra stability to the formulation 2.  
Morphological analysis by TEM demonstrated that MNPs are 
spherical in shape with sizes between 15-30 nm. Figure 3 shows 
a TEM micrography corresponding to nanocarrier 2, as example. 
In this case estimated size is between 5 and 10 nm and mainly 
corresponds to the magnetic core of the nanocarriers. 
In general, the values of nanoparticles sizes, determined by DLS 
(see Figure 1), remain higher than the one estimated by TEM 
due to an intrinsic sensitivity of DLS to determine small 
aggregates in dispersion which present lower diffusion 
electrophoretic coefficient 
15,17
. 
The ICP results revealed that the iron (from magnetite) content, 
expressed as mg Fe/mg MNP, in all the formulations was almost 
constant, of roughly 0.40 in average. 
Regarding to the magnetic properties, an exhaustive analysis 
was developed in earlier works
17,25
, then the same magnetic 
behaviour is expected and was qualitatively verified. 
 
Figure 3: TEM micrography corresponding to unloaded 
magnetic nanocarrier 2 
 
3.2 Z potential analysis: Proposed interacting mechanisms 
between carrier’s components.  
The evolution of Z potential as a function of the added GA 
concentration is depicted in Figure 4.  
 
Figure 4: Evolution of the Z potencial as a function of the 
nominal concentration of GA.*corresponds to the formulation 2 
containing 7.5% of GA under ultrasound treatment. 
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From the Figure it is clear that the surface charge diminishes as 
the concentration of GA increases. 
This behaviour could be ascribed to interactions between GA 
and positive charged amino groups from CS available in the 
surface. The partial neutralization of these positive charged 
moieties by crosslinking would increment the negative surface 
of MNPs. Crosslinker interacting functional groups could be 
associated with monomeric GA as well as its oligomers or even 
polymers of varied molecular weights 
23
.
 
When increasing GA concentration up to 15%, not significant 
differences in ζ values are observed, indicating a possible 
saturation of the amine available groups from polymeric phase. 
On the other hand it is noticeable the influence of the 
ultrasound treatment on the ζ of formulations containing 7.5% 
of GA. It is worth noting that the sample prepared by ultrasound 
exhibited a ζ lower than the similar prepared without 
ultrasound influence. This fact could be ascribed to the 
reduction of the aggregation during MNPs crosslinking leading 
to more available amine functional surface groups able to 
interact with GA moieties. 
AĐĐordiŶg to ʇ aŶd data regardiŶg to the other ĐharaĐterizatioŶ 
techniques a possible MNPs structure is proposed and included 
in Scheme 1. 
 
Scheme 1: Proposed MNPs structure. 
 
From the proposed structure and crosslinking mechanism it is 
deduced that interactions between CS and GA lead to the 
formation of stable imine bonds that would be the responsible 
in incrementing the stability of the nanocarriers by preventing 
polymer disggregation.  
 
3.3 Experimental parameters influencing Diclofenac 
incorporation 
The drug loading was assayed using formulation 2 .This sample 
was selected between the others regarding to its size and 
dispersability properties. 
Two procedures to incorporate Diclofenac were performed such 
as simple adsorption and covalent linkage by a coupling agent 
(GA). Further experimental conditions were evaluated using 
both incorporation routes, i.e the nature of the drug (using a 
commercial formulation (DA) and pure sodic Diclofenac (SD)) 
and its concentration as well as the GA concentration to 
promote covalent linkages between the drug and the carrier. 
Characterization results in terms of Dh, ʇ aŶd DLE reĐoǀered 
from this screening are shown in Table 1. 
Table 1: Diclofenac loading efficiency (DLE%), Dh and zeta 
potencial of all formulations obtained from varying different 
experimental conditions during drug encapsulation 
 
MNPs 
formulation 
Diclofenac 
form, 
quantity 
(mg/5mL) 
GA initial 
concentration
1
 
 
Dh (nm) / PDI 
 
ζ  
mV 
 
DLE 
% 
   Water Acetone   
Simple adsorption 
A DA, 25 --- 58.7/0.333 141.8/0.260 
-
15.1 
0 
B DA, 50 --- 255.0/0.263 122.4/0.472 1.79 11 
E SD, 25 --- 
825.0/ 
0.080 
458.7/0.282 
-
22.8 
33 
F SD, 50 --- 935/0,260 615/0.377 
-
24.1 
3,8 
Covalent linkage 
C DA, 25 50 uL 396.1/0.370 220/0.307 
-
28.0 
20 
D DA, 50 50 uL 615.0/0.210 955.0/0.297 
-
17.6 
8 
G SD, 25 50 uL 
149.3/ 
0.268 
235.9/0.348 
-
8.11 
27 
H SD , 25 100 uL 825/ 0,394 955.4/0.253 
-
3.30 
23 
1
Glutaraldehyde added as covalent linkage agent (µL/5mL) 
 
3.3.1. Incorporation route 
a. Simple Adsorption 
The physical adsorption was unsuccessful- or at least was not 
detected by UV/visible methods- employing commercial 
Diclofenac, using the lower initial concentration of drug. When 
such concentration was duplicated, the DLE increased to 
roughly 11%.  
ζ was almost -15.1 mV in the case of formulation A; which is 
similar to the one obtained for the unloaded nanocarriers. 
When duplicating the commercial drug amount, a significant 
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change in ζ value was registered. Surface charge turned into 
positive and could be considered as an evidence of drug 
incorporation, meaning that different functional groups 
remained exposed on surfaces of loaded MNPs.  
When pure SD was employed, the DLE increased significantly in 
comparison to the one registered using the commercial drug. 
This could be due to possible interferences referring to drug-
NPs surface interactions caused by excipients present in the 
commercial formulation. When concentration was incremented, 
DLE considerably diminished probably due to the saturation of 
available reactive sites on MNPs surface to interact with the SD. 
In a previous work a DLE greatly higher, of about 54%, was 
reached using almost similar experimental conditions
15
.
 
Differences are given by the chemical structure of the 
nanocarriers. In our earlier work the carriers were not 
crosslinked by GA. Therefore the NH2/NH3 and OH
-
 groups of CS 
remained accessible to interact with the drug. Whereas,  in 
present case, the crosslinking is restricting polymeric-drug 
interactions. Similar results have been found by other 
researchers using chitosan-GA crosslinked beads for controlled 
release of Diclofenac
24
.   
The variation on the sizes of the loaded MNPs obtained by 
simple adsorption is strongly dependent on the nature of the 
drug and its concentration. It is observed that the increment of 
drug leads to an enlargement of the MNPs. In such cases the 
nanosystems are better dispersed in organic media. These 
evidences correlate well with the data on surface charge and 
are related to the surface exposed functional groups when the 
drug is effectively incorporated. 
Using SD higher sized particles are obtained which could be 
ascribed to and increment of the aggregation caused by the 
presence of the drug moieties. 
b. Covalent linkage with glutaraldheyde 
The further addition of GA was performed to reinforce the drug-
MNPs bonds. In general an enhancement of the loaded 
capability was observed with respect to the simple adsorption 
procedure under similar experimental conditions.  
Exploring this loading procedure it is found that the loading 
levels are not improved by duplicating the drug concentration 
using either SD or DA drugs. Similar results have been reported 
by Boonsongrit et al.
16
. They have obtained nano and 
microparticles of CS for the controlled release of different 
drugs, including SD. They found an inverse ratio between the SD 
concentration and the loading level. They do not offer any 
justification for this observation. We propose that a saturation 
of the GA reactive sites occurred hence higher amounts of drug 
remain constant the DLE% or even reduced it by reaction with 
other moieties than the drug (DA). 
From the zeta potential data it appears that the surface charge 
is different from the corresponding to the loaded carrier using 
simple adsorption procedure. Inducing covalent linkage, 
negatively charged MNPs were obtained. By the first these data 
could be considered as a proof that the commercial Diclofenac 
was effectively incorporated to the MNPs. And on the other 
side, comparing the value and fundamentally the sign of the 
zeta potential with the one registered for formulation B, it could 
be corroborated the different mechanism that take place for 
the DS incorporation when the coupling agent was employed.  
Regarding to the average Dh, an increment is observed with 
respect to formulations prepared from simple adsorption. In 
general, this trend is a consequence of the GA used as coupling 
agent. As it was earlier mentioned, GA may form oligomers or 
polymers by interpenetration of its chains
23
.
 
 This fact would be the responsible of the increase in MNPs size, 
by forming a denser three-dimensional network structure. 
Examining the effect of the nature of the drug, formulations C 
and G (where the drug was incorporated on its pure form, SD) 
are compared. It is observed that although the DLE values are 
comparable, the Dh of G is considerably lower and even more 
when measuring in water. The zeta potential is also different 
since appear to be less negative in G regarding to C. These 
findings could be attributed to the different mechanism to 
linkage the SD to the MNPs surface.  
According to data on Table 1 the amount of GA added as 
coupling agent has not an influence on the % DLE, however the 
Dh of the MNPs greatly increase as GA concentration is higher. 
Figure 5 shows FTIR-DRIFTS, highlighting significant signals 
corresponding to this formulation in comparison to the one 
obtained without GA as covalent linker (E). The presence of 
MAG and crosslinked CS is confirmed by the presence of bands 
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corresponding to stretching vibration Fe-O of MAG and 
stretching vibration of N=C from the imine bond between GA 
and CS (See Figure 2). It is also observable the incorporation of 
DS (See Figure 5 for band assignments and Figure 2 to compare 
with the unloaded nanocarrier 2).  
The analysis included above clearly reveals that formulation G is 
the most suitable, in terms of DLE and size, for in vivo further 
assays.  
 
Figure 5: FTIR DRIFTS spectra of Diclofenac sodium (DS), loaded 
nanocarrier with DS (E) and DS loaded nanocarrier with GA as 
covalent linker (G). 
 
Scheme 2: Proposed interactions of Diclofenac with 
nanocarrier´s components 
 
3.3.2 Possible mechanisms for Diclofenac –MNPs interactions 
It is expected that GA anchors Diclofenac by its NH group and 
leaving exposed the COO- group. This is feasible, taking into 
account that GA trends to crosslink with amino groups by 
forming imine bonds or by ionic interactions
27
.
 
It is important to 
highlight that the loading procedure was performed at pH 6; 
and pKa of Diclofenac is about 4.15. Hence, deprotonation of 
the acid form occurred remained exposed the negative 
carboxylate group.  Therefore two possible interactions could 
take place: by GA-Diclofenac as was described above but also 
between the drug and the regions on the MNPs not covered by 
GA. That means with the amine groups of CS by electrostatic 
interactions. It is well known that the cosslinking process is not 
fully effective, then it is feasible that part of the polymeric 
phase still remains exposed
28
. 
3.4 Release data  
From previously performed analysis, formulation G has 
emerged as the most adequate in terms, not only of its loading 
capability but also from its stability and size properties. Hence it 
was selected for in vitro release tests. 
The assays were performed in presence and absence of an 
external magnetic field and the obtained profiles are shown in 
Figure 6. It is important to know the influence of the magnetic 
field in the drug release, taking into account that the potential 
applications of these nanosystems relies in their targeted 
guiding to the desired organ or tissue by a magnet. On the other 
hand, the study was developed under physiological pH in order 
to approximate the in vivo conditions where the formulation is 
thought to be employed for the treatment of localized 
inflammatory diseases.  
 
Figure 6: Cumulative percentage release of Diclofenac from G 
under the influence of a magnetic field. 
 
From the Figure it is appreciated that differences in the 
percentage of Diclofenac cumulative release during the entire 
assay is not greatly affected by the presence of a  magnetic 
field. After 24 hours, the drug release reached about 18% in 
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both conditions. Incomplete release of drugs from different 
carriers has been earlier reported. Ofokansi et al. found similar 
percentages for the release of Ibuprofen from microparticles 
composed by GA crosslinked chitosan
29
. V. Goncalves et al. have 
synthesized CS crosslinked with GA microspheres by a simple 
coacervation method for the controlled release of Diclofenac. 
Release study revealed that after 12 hours the drug released 
achieved 20%
30
. Similar results were found by Kulkarni et al. in 
their study based on the synthesis of CS microspheres in a w/o 
emulsion followed by crosslinking with different agents such as 
viz, GA and sulfuric acid
24
. Diclofenac loading between 23 and 
30% were achieved with GA, finding the slowest release profile 
for this crosslinker agent among the others.  
Among these data it is possible verify the strong covalent 
linkage promoting by the addition of GA, demonstrating that 
the interactions drug-carriers resulted relevant regarding to the 
pharmacokinetic of the formulation. For instance a previous 
work the release profile of Diclofenac physically adsorbed to 
MNPs composed by magnetite functionalized with OA acid and 
CS was explored and drug release reached 75% of the total 
NSAID loaded, after 24 hours of incubation in PBS buffer
15
.    
This behavior for Diclofenac release is interesting in terms of 
stability of the formulation: the delayed in vitro release would 
allow a more sustainable availability of the drug in time in the 
desired organ when extrapolating these results to in vivo 
conditions. By this way, the formulation would involve lower 
doses to achieve the physiological activity of the drug. Both 
directionality imparted by magnetism and sustained release in 
time could result in interesting synergic characteristics for 
potential in vivo applications.   
The analysis of the results obtained by the application of 
different fitting kinetic models for drug release is listed in Table 
2. These data reveal that the Korsmeyer model better fits 
Diclofenac release from MNPs in both explored conditions 
(absence and presence of a magnetic field).  This model explains 
the release from swelling controlled systems, which means that 
liberation of the drug incorporated onto a swellable hydrophilic 
polymer occurs by concomitant sorption of water and 
desorption of the therapeutic agent
31
 .   
On the other hand, the use of GA changes the kinetic release of 
the drug in comparison to the non-containing GA nanocarrier. 
Since in this last case, the kinetic release was better fitted by 
the first order kinetic model as was reported elsewhere
15
. 
 
4. CONCLUSION 
In this work different experimental conditions were assayed in 
order to improve the stability and loading ability of a magnetic 
nanocarrier composed by magnetite, oleic acid and chitosan for 
Diclofenac target and delivery. The screening of different 
glutaraldehyde concentrations as crosslinking agent permitted 
the selection of an optimum and stable formulation with a 
suitable size for in vivo applications. It was found that 
ultrasound treatment during crosslinking process greatly 
stabilize and improve the size of the carriers.  
Exploring different conditions regarding to the incorporation of 
Diclofenac, a nanocarrier of size lower than 150 nm, with 
satisfactory loading skill (almost 30%) and with high dispersion 
capability on water was obtained. The characterization data 
allowed proposed potential mechanisms for both stabilization 
of MNPs with GA and interactions with the therapeutic agent. 
 Diclofenac release kinetic studies demonstrated that the 
magnetic field has not influence of the way in that the drug was 
released. This result is very interesting taking into account that 
the magnetic guidance of the particles has not an effect on the 
pharmacokinetic of the drug.  
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